Close Menu

This article has been updated from a previous version to include comments made by Veracyte executives during the company's earnings call.

NEW YORK – Genomic testing firm Veracyte reported after the close of the market Tuesday that its third quarter 2019 revenues grew 32 percent year over year.

For the three months ended Sept. 30, the South San Francisco, California-based firm reported total revenues of $31.0 million, compared to $23.5 million in Q3 2018, beating analysts' average estimate of $30.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.